UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: March 9, 2023

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

 

 

 

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x Form 20-F ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

On March 9, 2023, Biophytis S.A. issued a press release presenting positive results of Phase 2-3 COVA Study at ERS 2023 21st Lung Science Conference. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit   Description
99.1   Press Release dated March 9, 2023.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOPHYTIS S.A.
     
Date: March 9, 2023 By: /s/ Stanislas Veillet
    Name: Stanislas Veillet
    Title: Chairman and Chief Executive Officer

 

 

 

Biophytis (NASDAQ:BPTS)
Historical Stock Chart
From Mar 2025 to Apr 2025 Click Here for more Biophytis Charts.
Biophytis (NASDAQ:BPTS)
Historical Stock Chart
From Apr 2024 to Apr 2025 Click Here for more Biophytis Charts.